Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combined With Lenvatinib and GEMOX in Unresectable Biliary Tract Tumors
NCT06892925Phase 2Active, not recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in biliary tract cancer (BTC), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Objective Response Rate at 4 years. Started Jun 2025; status: active, not recruiting.
02
Drugs
QL1706
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06892925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892925.